Arrowhead Pharmaceuticals (ARWR) investor relations material

Strategic priorities and commercial focus

• Transitioned from R&D to commercial organization, emphasizing cardiometabolic space and late-stage R&D investments for 2026–2027.

• Main focus is commercial execution, especially with the upcoming phase III readouts for SHTG and the drug plozasiran (Redemplo).

• Expanding commercial footprint due to promising early commercial results and ongoing disease education efforts.

• Early-stage pipeline includes obesity, Alzheimer's (tau program), and a dual siRNA dimer targeting LDL and triglycerides.

• First-in-man data for dual siRNA dimer could be transformational for ASCVD treatment.

Market opportunity and patient identification

• FCS is an ultra-rare, underdiagnosed condition, with current U.S. patient estimates well above 6,000 due to improved identification.

• Patients are identified via standard lipid panels and proprietary methods, with both genetic and clinical diagnoses considered.

• Less than 10% market penetration so far, with ongoing education and identification efforts.

• Early launch has seen several hundred prescriptions, including switches from competitors, driven by efficacy, tolerability, and convenience.

• APOC3 inhibitor class is seen as transformational for patients, reducing hospitalizations and improving quality of life.

European market and pricing strategy

• Positive CHMP opinion for Redemplo in both genetic and clinical FCS, with EMA approval expected soon.

• EU launch will proceed country by country, starting with Germany, over the next 12 months.

• Recent price adjustment to $45,000 WAC was well received by payers, aligning with competitor pricing and supporting ongoing discussions.

• Plan to maintain this price for future indications, pending upcoming data readouts.